Global Duchenne Muscular Dystrophy Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2022 to 2028

Description

List of Tables

Value Market Research deeply researched the Global Duchenne Muscular Dystrophy Treatment Market to foresee a significant growth in the industry over the upcoming years. The global duchenne muscular dystrophy treatment market report provides a complete industry analysis, market size, market share, growth trends, and forecasts for 2023 to 2028. The report starts with a detailed market introduction and an executive summary that highlights the report's key growth numbers. The subsequent chapters discuss the value chain of the market, Porter's Five Forces Model, and market attractiveness analysis. An exclusive chapter on COVID-19 impact analysis has been added to understand how the market has responded to the pandemic.

The market dynamics section of the report elaborates the current market drivers, restraints along with the challenges/risks and upcoming opportunities. This section can be of high interest for any company's strategists and new product development department. The global duchenne muscular dystrophy treatment market study segments the market and provides the market size in terms of revenue and/ or sales. This data is bifurcated by region and later by countries. The data is collected through detailed primary interviews and industry experts across the world. The detailed methodology can be seen in our sample reports. These market estimates are also influenced by the latest social, political and economic changes along with the current market dynamics that are affecting this duchenne muscular dystrophy treatment market.

The next sections of the duchenne muscular dystrophy treatment market report studies the market competitiveness and profiles some key market players/manufacturers. These sections are knowledgeable for understanding the competitor's product-line, their financials, recent developments and the top market share owners in the industry.

Countries Covered in the report are as below:

North America- United States, Canada, and Mexico

Europe- United Kingdom, Germany, France, Italy, Russia, Spain & Rest of Europe

Asia-Pacific- China, India, Japan, South Korea, Australia & Rest of APAC

Latin America- Brazil, Argentina, Peru, Chile & Rest of Latin America

Middle East and Africa- Saudi Arabia, UAE, Israel, South Africa

Market Segmentation in the report is as below:

By Product Type

Pain Management Drugs
Corticosteroids
NSAIDs

By Application

Mutation Suppression
Exon Skipping Approach

By End User

Hospitals
Home Care Settings
Clinics

Product Code: VMR11218127

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . DUCHENNE MUSCULAR DYSTROPHY TREATMENT - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product Type
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By End User
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

5.1. Impact Analysis of Covid-19 Outbreak
- 5.1.1. Direct Impact on Production
- 5.1.2. Supply Chain and Market Disruption
- 5.1.3. Financial Impact on Firms and Financial Markets
5.2. COVID-19 Impact Analysis by Production, Import, Export and Demand
5.3. Market: Pre V/S Post COVID-19
5.4. Estimated Impact of the Coronavirus (COVID-19) Epidemic
5.5. COVID-19: Micro and Macro Factor Analysis

6 . GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET ANALYSIS BY PRODUCT TYPE

6.1 Overview by Product Type
6.2 Historical and Forecast Data
6.3 Analysis by Product Type
6.4 Pain Management Drugs Historic and Forecast Sales by Regions
6.5 Corticosteroids Historic and Forecast Sales by Regions
6.6 NSAIDs Historic and Forecast Sales by Regions

7 . GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET ANALYSIS BY APPLICATION

7.1 Overview by Application
7.2 Historical and Forecast Data
7.3 Analysis by Application
7.4 Mutation Suppression Historic and Forecast Sales by Regions
7.5 Exon Skipping Approach Historic and Forecast Sales by Regions

8 . GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET SALES ANALYSIS BY END USER

8.1 Overview by End User
8.2 Historical and Forecast Data
8.3 Analysis by End User
8.4 Hospitals Historic and Forecast Sales by Regions
8.5 Home Care Settings Historic and Forecast Sales by Regions
8.6 Clinics Historic and Forecast Sales by Regions

9 . GLOBAL DUCHENNE MUSCULAR DYSTROPHY TREATMENT MARKET SALES ANALYSIS BY GEOGRAPHY

9.1. Regional Outlook Sales Analysis
9.2. Introduction Sales Analysis
9.3. North America Sales Analysis
- 9.3.1. Overview, Historic and Forecast Sales Analysis
- 9.3.2. North America By Segment Sales Analysis
- 9.3.3. North America By Country Sales Analysis
- 9.3.4. United State Sales Analysis
- 9.3.5. Canada Sales Analysis
- 9.3.6. Mexico Sales Analysis
9.4. Europe Sales Analysis
- 9.4.1. Overview, Historic and Forecast Sales Analysis
- 9.4.2. Europe by Segment Sales Analysis
- 9.4.3. Europe by Country Sales Analysis
- 9.4.4. United Kingdom Sales Analysis
- 9.4.5. France Sales Analysis
- 9.4.6. Germany Sales Analysis
- 9.4.7. Italy Sales Analysis
- 9.4.8. Russia Sales Analysis
- 9.4.9. Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
- 9.5.1. Overview, Historic and Forecast Sales Analysis
- 9.5.2. Asia Pacific by Segment Sales Analysis
- 9.5.3. Asia Pacific by Country Sales Analysis
- 9.5.4. China Sales Analysis
- 9.5.5. India Sales Analysis
- 9.5.6. Japan Sales Analysis
- 9.5.7. South Korea Sales Analysis
- 9.5.8. Australia Sales Analysis
- 9.5.9. Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
- 9.6.1. Overview, Historic and Forecast Sales Analysis
- 9.6.2. Latin America by Segment Sales Analysis
- 9.6.3. Latin America by Country Sales Analysis
- 9.6.4. Brazil Sales Analysis
- 9.6.5. Argentina Sales Analysis
- 9.6.6. Peru Sales Analysis
- 9.6.7. Chile Sales Analysis
- 9.6.8. Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
- 9.7.1. Overview, Historic and Forecast Sales Analysis
- 9.7.2. Middle East & Africa by Segment Sales Analysis
- 9.7.3. Middle East & Africa by Country Sales Analysis
- 9.7.4. Saudi Arabia Sales Analysis
- 9.7.5. UAE Sales Analysis
- 9.7.6. Israel Sales Analysis
- 9.7.7. South Africa Sales Analysis
- 9.7.8. Rest Of Middle East And Africa Sales Analysis

10 . COMPETITIVE LANDSCAPE OF THE DUCHENNE MUSCULAR DYSTROPHY TREATMENT COMPANIES

10.1. Duchenne Muscular Dystrophy Treatment Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments

11 . COMPANY PROFILES OF DUCHENNE MUSCULAR DYSTROPHY TREATMENT INDUSTRY

11.1. Top 10 Company Share Analysis
11.2. Market Concentration Rate
11.3. Acceleron Pharma Inc.
- 11.3.1. Company Overview
- 11.3.2. Company Revenue
- 11.3.3. Products
- 11.3.4. Recent Developments
11.4. Akashi Therapeutics Inc.
- 11.4.1. Company Overview
- 11.4.2. Company Revenue
- 11.4.3. Products
- 11.4.4. Recent Developments
11.5. BioMarin Pharmaceutical Inc.
- 11.5.1. Company Overview
- 11.5.2. Company Revenue
- 11.5.3. Products
- 11.5.4. Recent Developments
11.6. Bristol-Myers Squibb Company
- 11.6.1. Company Overview
- 11.6.2. Company Revenue
- 11.6.3. Products
- 11.6.4. Recent Developments
11.7. Eli Lilly and Company
- 11.7.1. Company Overview
- 11.7.2. Company Revenue
- 11.7.3. Products
- 11.7.4. Recent Developments
11.8. Janssen Pharmaceuticals Inc.
- 11.8.1. Company Overview
- 11.8.2. Company Revenue
- 11.8.3. Products
- 11.8.4. Recent Developments
11.9. Lexicon Pharmaceuticals Inc.
- 11.9.1. Company Overview
- 11.9.2. Company Revenue
- 11.9.3. Products
- 11.9.4. Recent Developments
11.10. Nippon Shokubai Co. Ltd.
- 11.10.1. Company Overview
- 11.10.2. Company Revenue
- 11.10.3. Products
- 11.10.4. Recent Developments
11.11. Nobelpharma Co. Ltd.
- 11.11.1. Company Overview
- 11.11.2. Company Revenue
- 11.11.3. Products
- 11.11.4. Recent Developments
11.12. Pfizer Inc.
- 11.12.1. Company Overview
- 11.12.2. Company Revenue
- 11.12.3. Products
- 11.12.4. Recent Developments
11.13. PTC Therapeutics Inc.
- 11.13.1. Company Overview
- 11.13.2. Company Revenue
- 11.13.3. Products
- 11.13.4. Recent Developments
11.14. Sarepta Therapeutics Inc.
- 11.14.1. Company Overview
- 11.14.2. Company Revenue
- 11.14.3. Products
- 11.14.4. Recent Developments
11.15. Taiho Pharmaceutical Co. Ltd.
- 11.15.1. Company Overview
- 11.15.2. Company Revenue
- 11.15.3. Products
- 11.15.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies